Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
<p>Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>
Saved in:
| Hovedforfatter: | |
|---|---|
| Andre forfattere: | , , , , , , , , , , , , |
| Udgivet: |
2025
|
| Fag: | |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
| _version_ | 1849927643375337472 |
|---|---|
| author | Seyed Reza Mousavi (13223324) |
| author2 | Alihasan Rahmani (22676321) Maryam Amini Pouya (22676324) Elnaz Zabihi Eidgahi (22676327) Mohamad Delirrad (22676330) Hamed Hosseini (3480455) Alireza Ghassemi Toussi (22676333) Behnaz Hedayatjoo (22676336) Seyyedeh Maryam Afshani (22676339) Mohammad Amin Ghobadi (22676342) Mohammad Reza Shahidi (22676345) Seyed Amirhossein Mousavi (22676348) Maryam Barghbani (22676351) Mahdi Jannati Yazdan Abad (22676354) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Seyed Reza Mousavi (13223324) Alihasan Rahmani (22676321) Maryam Amini Pouya (22676324) Elnaz Zabihi Eidgahi (22676327) Mohamad Delirrad (22676330) Hamed Hosseini (3480455) Alireza Ghassemi Toussi (22676333) Behnaz Hedayatjoo (22676336) Seyyedeh Maryam Afshani (22676339) Mohammad Amin Ghobadi (22676342) Mohammad Reza Shahidi (22676345) Seyed Amirhossein Mousavi (22676348) Maryam Barghbani (22676351) Mahdi Jannati Yazdan Abad (22676354) |
| author_role | author |
| dc.creator.none.fl_str_mv | Seyed Reza Mousavi (13223324) Alihasan Rahmani (22676321) Maryam Amini Pouya (22676324) Elnaz Zabihi Eidgahi (22676327) Mohamad Delirrad (22676330) Hamed Hosseini (3480455) Alireza Ghassemi Toussi (22676333) Behnaz Hedayatjoo (22676336) Seyyedeh Maryam Afshani (22676339) Mohammad Amin Ghobadi (22676342) Mohammad Reza Shahidi (22676345) Seyed Amirhossein Mousavi (22676348) Maryam Barghbani (22676351) Mahdi Jannati Yazdan Abad (22676354) |
| dc.date.none.fl_str_mv | 2025-11-24T18:24:15Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pgph.0004281.t003 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Adverse_events_during_follow-up_period_in_Phase_III_non-inferiority_clinical_trial_of_SnaFab_compared_to_Razi_antivenom_in_snakebites_/30696611 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent |
| dc.title.none.fl_str_mv | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_8a03b27cbcc354e71c30a2b2a4a1ae75 |
| identifier_str_mv | 10.1371/journal.pgph.0004281.t003 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30696611 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.Seyed Reza Mousavi (13223324)Alihasan Rahmani (22676321)Maryam Amini Pouya (22676324)Elnaz Zabihi Eidgahi (22676327)Mohamad Delirrad (22676330)Hamed Hosseini (3480455)Alireza Ghassemi Toussi (22676333)Behnaz Hedayatjoo (22676336)Seyyedeh Maryam Afshani (22676339)Mohammad Amin Ghobadi (22676342)Mohammad Reza Shahidi (22676345)Seyed Amirhossein Mousavi (22676348)Maryam Barghbani (22676351)Mahdi Jannati Yazdan Abad (22676354)MedicineCell BiologyNeurosciencePhysiologyPharmacologyBiotechnologyImmunologyScience PolicyMental Healthpatients received eitherday monitoring periodtotal antivenom consumptiontreating snakebite envenomationantivenom units administeredrazi antivenom groupsnakebite envenomationrazi antivenomrazi groupantivenom infusion49 units40 unitssnafab antivenomrazi antivenomssnafab groupserum sicknessrecovery rateprimary endpointmuscle weaknessmean numbermay 15thapril 17thanaphylactic shockadverse events98 %).92 ).27 ).100 percent<p>Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>2025-11-24T18:24:15ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1371/journal.pgph.0004281.t003https://figshare.com/articles/dataset/Adverse_events_during_follow-up_period_in_Phase_III_non-inferiority_clinical_trial_of_SnaFab_compared_to_Razi_antivenom_in_snakebites_/30696611CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/306966112025-11-24T18:24:15Z |
| spellingShingle | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. Seyed Reza Mousavi (13223324) Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent |
| status_str | publishedVersion |
| title | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. |
| title_full | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. |
| title_fullStr | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. |
| title_full_unstemmed | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. |
| title_short | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. |
| title_sort | Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. |
| topic | Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent |